Cardiac progenitor cells and bone marrow-derived very small embryonic-like stem cells for cardiac repair after myocardial infarction.
Heart failure after myocardial infarction (MI) continues to be the most prevalent cause of morbidity and mortality worldwide. Although pharmaceutical agents and interventional strategies have contributed greatly to therapy, new and superior treatment modalities are urgently needed given the overall disease burden. Stem cell-based therapy is potentially a promising strategy to lead to cardiac repair after MI. An array of cell types has been explored in this respect, including skeletal myoblasts, bone marrow (BM)-derived stem cells, embryonic stem cells, and more recently, cardiac progenitor cells (CPCs). Recently studies have obtained evidence that transplantation of CPCs or BM-derived very small embryonic-like stem cells can improve cardiac function and alleviate cardiac remodeling, supporting the potential therapeutic utility of these cells for cardiac repair. This report summarizes the current data from those studies and discusses the potential implication of these cells in developing clinically-relevant stem cell-based therapeutic strategies for cardiac regeneration.
Tang
Xian-Liang
XL
Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY 40292, USA. xltang@louisville.edu
Rokosh
D Gregg
DG
Guo
Yiru
Y
Bolli
Roberto
R
D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology*; D048429:Cell Size; D006334:Heart Function Tests; D006801:Humans; D009203:Myocardial Infarction / Q000473:pathology* / Q000628:therapy*; D032383:Myocytes, Cardiac / Q000166:cytology*; D020127:Recovery of Function; D012038:Regeneration; D033581:Stem Cell Transplantation